Search Results
Found 3 results
510(k) Data Aggregation
(41 days)
The Hemoglobin FASC Variant Control kit contains HbA, HbF, HbS and HbC. The control is intended as a position marker for hemoglobin variant analysis methods such as ion exchange HPLC, capillary electrophoresis, cellulose acetate and agar/agarose gel electrophoresis. The Hemoglobin FASC control will assist in defining the elution time on HPLC or capillary electrophoresis or migration distance on electrophoresis. In this way the common hemoglobin variants can be identified and rare variants that elute close to these can be distinguished for further characterization.
The control is for in vitro diagnostic use only and should not be used past the expiry date.
The Hemoglobin FASC Variant Control kit contains HbA, HbF, HbS and HbC. It contains stabilizers and preservatives to maintain the stability of the hemoglobin variants. The product is provided in a lyophilized form and is reconstituted with 1.0 ml of reconstitution fluid (0.09% sodium azide) prior to use.
The provided text describes a Hemoglobin FASC Variant Control (extendSURE™ HbFASC Control) and its 510(k) submission. However, it does not contain information about acceptance criteria, a study proving the device meets acceptance criteria, or any details related to AI/algorithm performance studies.
Instead, the document focuses on:
- Device Summary: Describing the device, its intended use, and its classification.
- Predicate Device Comparison: Establishing substantial equivalence to previously cleared devices based on analyte composition and intended uses.
- Performance Characteristics (Stability): Reporting results of stability studies that support the shelf life claims.
- FDA Clearance Letter: Confirming the 510(k) clearance and the regulatory classification.
- Indications for Use: Formal statement of the device's intended applications.
Therefore, I cannot fulfill your request for information regarding acceptance criteria and studies proving the device meets them, sample sizes for test/training sets, expert details, adjudication methods, MRMC studies, standalone algorithm performance, or ground truth establishment, as this information is not present in the provided text.
The only "performance characteristic" explicitly mentioned is:
1. A table of acceptance criteria and the reported device performance
| Acceptance Criteria | Reported Device Performance (Stability) |
|---|---|
| Not specified | Shelf life (closed vial) at 2° to 8°C of 36 months from manufacture. |
| Not specified | Open vial (reconstituted) stability of 6 weeks at 2° to 8°C. |
For all other points, the information is not available in the provided text.
2. Sample size used for the test set and the data provenance: Not provided.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not provided.
4. Adjudication method for the test set: Not provided.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: No AI component or MRMC study mentioned.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: No AI component or standalone algorithm performance mentioned.
7. The type of ground truth used: Not applicable as it's a control material, and "ground truth" for a diagnostic algorithm is not relevant here. The "performance" is about its stability and ability to serve as a marker.
8. The sample size for the training set: Not applicable as it's not an AI/algorithm device that requires a training set.
9. How the ground truth for the training set was established: Not applicable.
Ask a specific question about this device
(45 days)
Ask a specific question about this device
(112 days)
Abuscreen ONLINE for Phencyclidine is an in vitro diagnostic test for the qualitative and semiquantitative detection of phencyclidine and its metabolites in human urine on the Hitachi 917 analyzer at a cutoff concentration of 25 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Measurements obtained by this device are used in the diagnosis of phencyclidine use or abuse.
Abuscreen ONLINE for Phencyclidine is an in vitro diagnostic test for the qualitative and semiquantitative detection of phencyclidine and its metabolites in human urine on automated clinical chemistry analyzers at a cutoff concentration of 25 ng/mL. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Measurements obtained by this device are used in the diagnosis of phencyclidine use or abuse.
The proposed Abuscreen ONLINE Phencyclidine test kit is specifically intended for use on the Hitachi 917 Analyzer and future similar analyzer models. It was adapted from the currently marketed Abuscreen ONLINE Phencyclidine test kit. The labeling and packaging have been changed for use on the Hitachi 917 Analyzer as well as an addition of a surfactant to the diluent. This modified test kit is not a replacement to the currently marketed kit.
The Hitachi 917 Analyzer System is a fully automatic, computer-controlled system for clinical chemistry. It was conceived for both quantitative and qualitative in vitro determination using a large variety of tests for analysis, e.g. in serum and urine. Integrated in the system is an ion-selective unit for determination of electrolytes. The throughput per hour is 800 tests for clinical chemistry (1200 with electrolytes). The system consists of the analyzer which performs all functions required for fully automatic sample and testprocessing. Beginning with the automatic recording of patient samples - provided that they are supplied in barcode-labeled vessels - up to the photometric measurement and results transmission to the computer unit.
1. Table of Acceptance Criteria and Reported Device Performance
| Performance Characteristic | Acceptance Criteria (Proposed for Hitachi 917) | Reported Device Performance (Abuscreen ONLINE Phencyclidine for Hitachi 917) | Predicate Device Performance (Abuscreen ONLINE Phencyclidine K920935) |
|---|---|---|---|
| Precision Qualitative | >95% negative at 18.75 ng/mL>95% positive at 31.25 ng/mL | >95% negative at 18.75 ng/mL>95% positive at 31.25 ng/mL | >95% negative at 20 ng/mL>95% positive at 30 ng/mL |
| Precision (Within Run) - OD (CV%) | Not explicitly stated as acceptance criteria, but reported values are compared to predicate. | 12.5 ng/mL: 2.9%18.75 ng/mL: 3.3%25.0 ng/mL: 1.8%31.25 ng/mL: 2.0%37.5 ng/mL: 1.2% | Not provided in terms of individual CVs for predicate, only qualitative stated. |
| Precision (Day-to-Day) - OD (CV%) | Not explicitly stated as acceptance criteria, but reported values are compared to predicate. | 12.5 ng/mL: 3.3%18.75 ng/mL: 4.8%25.0 ng/mL: 3.5%31.25 ng/mL: 3.3%37.5 ng/mL: 3.1% | Not provided in terms of individual CVs for predicate, only qualitative stated. |
| Precision (Within Run) - Quantitative (CV%) | Not explicitly stated as acceptance criteria, but reported values are compared to predicate. | 12.5 ng/mL: 6.2%18.75 ng/mL: 4.3%25.0 ng/mL: 2.0%31.25 ng/mL: 2.1%37.5 ng/mL: 1.9% | 12.5 ng/mL: 7%18.75 ng/mL: 6%25.0 ng/mL: 3%31.25 ng/mL: 3% |
| Precision (Day-to-Day) - Quantitative (CV%) | Not explicitly stated as acceptance criteria, but reported values are compared to predicate. | 12.5 ng/mL: 8.6%18.75 ng/mL: 6.6%25.0 ng/mL: 5.0%31.25 ng/mL: 4.0%37.5 ng/mL: 3.4% | 12.5 ng/mL: 10%18.75 ng/mL: 5%25.0 ng/mL: 3%31.25 ng/mL: 3% |
| Accuracy (25 ng/mL Cutoff) | Not explicitly stated as a numerical acceptance criterion, but demonstrated by agreement with confirmed samples. | N=50 Confirmed Pos.: 50 Pos., 0 Neg.N=14 (25% above cutoff): 14 Pos., 0 Neg.N=14 (25% below cutoff): 0 Pos., 14 Neg. | N=75 Confirmed Pos.: 75 Pos., 0 Neg. |
| Limit of Detection | Comparability to predicate device. | 0.6 ng/mL | 6 ng/mL (clinical sensitivity) |
2. Sample Size Used for the Test Set and Data Provenance
- Test Set Sample Size:
- Precision (Qualitative & Quantitative): The document reports "Mean (OD)" and "Mean (ng/mL)" values for various concentrations (12.5, 18.75, 25.0, 31.25, 37.5 ng/mL) under "Within Run" and "Day-to-Day" conditions. While the exact number of replicates per run/day isn't explicitly stated, the CV% values indicate multiple measurements were taken for each concentration.
- Accuracy:
- N = 50 confirmed positive samples.
- N = 14 samples diluted within 25% above cutoff concentration.
- N = 14 samples diluted within 25% below cutoff concentration.
- Data Provenance: The document does not specify the country of origin of the data or whether the study was retrospective or prospective. It presents the data as performance characteristics obtained from clinical and nonclinical studies.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
The document does not provide information on the number of experts used or their qualifications for establishing ground truth. The "Confirmed Pos." in the Accuracy section implies a confirmatory method was used, but the details of who performed this confirmation and their expertise are not given.
4. Adjudication Method for the Test Set
The document does not describe any specific adjudication method (e.g., 2+1, 3+1, none) for the test set.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No MRMC comparative effectiveness study is mentioned. This device is an in vitro diagnostic test for chemical analysis, not an imaging device requiring human reader interpretation in the same way.
6. Standalone Performance (Algorithm Only without Human-in-the-Loop Performance)
Yes, the study describes the standalone performance of the Abuscreen ONLINE Phencyclidine for Hitachi 917 device. The precision and accuracy data reflect the performance of the automated system operating independently. The "semisuantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program," indicating the automated nature of the results.
7. Type of Ground Truth Used
The ground truth for the "Accuracy" section was established by "Confirmed Pos." meaning it was likely confirmed by an independent, more definitive analytical method, although the specific method (e.g., GC/MS) is not explicitly named. It is based on analytical confirmation rather than pathology or outcome data.
8. Sample Size for the Training Set
The document does not explicitly mention a "training set" or its sample size. This type of device (enzyme immunoassay) is typically characterized and validated rather than trained in the machine learning sense. The data presented are for evaluating the performance of the developed assay.
9. How the Ground Truth for the Training Set Was Established
As no training set is described for this type of device, the method for establishing ground truth for a training set is not applicable or provided. The "ground truth" in this context refers to accurately known concentrations of phencyclidine in samples used for validation and verification, which would be established through highly accurate analytical methods.
Ask a specific question about this device
Page 1 of 1